Maximizing the Clinical Benefit of TGCT Medical Therapies
Maximizing the Clinical Benefit of TGCT Medical Therapies is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jan 31, 2023
Termination Date: Jan 30, 2024
Activity Goal:
The goal of this activity is to discuss evidence for use of CSF1R-targeting agents for the treatment of patients with TGCT, including examination of agents in development, to help clinicians manage this condition to improve patient outcomes.
Learning Objective(s):
• Describe the latest scientific data on approved and emerging targeted therapies for the management of recurrent or diffuse tenosynovial giant cell tumor (TGCT).
• Apply medical treatment for appropriate patients with TGCT in a manner that maximizes the benefit/risk balance and is consistent with current labeling and recommendations.
• Address safety concerns related to the use of TGCT targeted therapies through proactive patient monitoring, and identification and management of adverse events.
Additional details will be posted as soon as information is available.